Ulcerative colitis (UC) has become a worldwide public health problem, and the prevalence of the disease among children has been increasing. The pathogenesis of UC has not been elucidated, but dysbiosis of the gut microbiota is considered the main cause of chronic intestinal inflammation. This review focuses on the therapeutic effects of probiotics on UC and the potential mechanisms involved. In animal studies, probiotics have been shown to alleviate symptoms of UC, including weight loss, diarrhea, blood in the stool, and a shortened colon length, while also restoring intestinal microecological homeostasis, improving gut barrier function, modulating the intestinal immune response, and attenuating intestinal inflammation, thereby providing theoretical support for the development of probiotic-based microbial products as an adjunctive therapy for UC. However, the efficacy of probiotics is influenced by factors such as the bacterial strain, dose, and form. Hence, the mechanisms of action need to be investigated further. Relevant clinical trials are currently lacking, so the extension of animal experimental findings to clinical application requires a longer period of consideration for validation.
12 September 2024 in Frontiers in Gastroenterology
Inflammatory bowel disease (IBD) comprises Crohn’s disease (CD) and ulcerative colitis (UC), both characterized by chronic intestinal inflammation and an elevated risk of colorectal cancer due to persistent inflammation. The Regenerating gene (Reg) family proteins exhibit properties that promote cell proliferation, inhibit apoptosis, reduce inflammation, combat microbial infections, and potentially modulate the immune system. There is increasing evidence of the potential function of the Reg family of proteins in the development of IBD and colorectal cancer, but the exact mechanism of action of the Reg family of proteins has not yet been fully clarified. In this paper, we reviewed the Reg protein family’s involvement in the development of IBD by regulating intestinal microbes and immunity to maintain intestinal homeostasis. We also explored its possible regulatory mechanisms and signaling pathways in the progression and treatment of colorectal cancer, which is expected to serve as a target and a new biomarker for the treatment of IBD and colorectal cancer in the future.
The circadian rhythm, a 24-h cycle, plays a crucial role in regulating gut physiological processes, particularly the proliferation and differentiation of intestinal epithelial cells, which are essential for gut homeostasis and repair. This review discusses the complex interactions between circadian rhythms, cell cycle regulation, and key signaling pathways (Wnt, Notch, and Hippo) in the context of the intestinal stem cell niche and epithelial cell fate decisions. Key molecules such as brain and muscle ARNT-like 1 (BMAL1), circadian locomotor output cycles kaput (CLOCK), hairy and enhancer of split 1 (Hes1), and Yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ) coordinate stem cell functions with circadian rhythms. We discuss how Notch signaling regulates the cell cycle and interacts with circadian rhythms. Additionally, we explore the role of Hippo-Wnt signaling in balancing cell proliferation and differentiation. Furthermore, we highlight the intricate relationships between circadian clock components and signaling pathways, emphasizing the importance of temporal coordination in determining epithelial cell fate. We also discuss shared enzymes, including casein kinase 1 delta (CK1δ), glycogen synthase kinase 3 (GSK3), and AMP-activated protein kinase (AMPK), which play a role in regulating the cell cycle, circadian rhythm, and signaling pathways. In summary, this review offers valuable insights into the regulatory mechanisms that control stem cell behavior and epithelial cell differentiation, suggesting promising directions for future research in intestinal biology and tissue homeostasis.
19 January 2019 in Journal of Paediatrics and Child Health
Purpose: Helicobacter pylori (HP) infection is an identified risk factor for pediatric chronic gastritis (PCG), but its impact on gastric juice microbiota (GJM) remains to be further elucidated in PCG. This study aimed to analyze and compare the microbial communities and microbial interactive networks of GJM in PCG that clinically tested positive and negative for HP (HP+ and HP−, respectively).Methods: A total of 45 PCG patients aged from 6 to 16 years were recruited, including 20 HP+ and 25 HP− patients tested by culture and rapid urease test. Gastric juice samples were collected from these PCG patients and subjected to high-throughput amplicon sequencing and subsequent analysis of 16S rRNA genes.Results: While no significant change in alpha diversity, significant differences in beta diversity were observed between HP+ and HP− PCG. At the genus level, Streptococcus, Helicobacter, and Granulicatella were significantly enriched in HP+ PCG, whereas Campylobacter and Absconditabacteriales (SR1) were significantly enriched in HP− PCG. Network analysis showed that Streptococcus was the only genus positively correlated with Helicobacter (r = 0.497) in the GJM network of overall PCG. Moreover, compared to HP− PCG, HP+ PCG showed a reduction in microbial network connectivity in GJM. Netshift analysis identified driver microbes including Streptococcus and other four genera, which substantially contributed to the GJM network transition from HP− PCG to HP+ PCG. Furthermore, Predicted GJM function analysis indicated up-regulated pathways related to the metabolism of nucleotides, carbohydrates, and L-Lysine, the urea cycle, as well as endotoxin peptidoglycan biosynthesis and maturation in HP+ PCG.Conclusion: GJM in HP+ PCG exhibited dramatically altered beta diversity, taxonomic structure, and function, with reduced microbial network connectivity, which could be involved in the disease etiology.
Preliminary studies have demonstrated the potential of Bifidobacterium longum (B. longum) BAA2573 in alleviating dextran sulfate sodium (DSS)-induced colitis; however, the underlying mechanisms are still unclear. To investigate the intestinal immune responses and molecular changes upon B. Longum BAA2573 treatment. C57BL/6 J mice (6–8 weeks) were divided into three groups, control (CON), DSS, and B. longum BAA2573 intervention group (B + DSS). The B + DSS group was pretreated with B. longum BAA2573 for six days before induction with DSS. The body weight, stool characteristics, and disease activity index were recorded daily. After the 12-day intervention, the colonic tissues and serum from each group were collected for further analysis. Immunofluorescence assay was conducted to detect the infiltration of macrophages. qPCR and ELISA were used to analyze the expression of cytokines, RNA‑seq and subsequent qPCR were employed for the detection and validation of differentially expressed genes (DEGs), respectively. The crosstalk between DEGs and metabolites was also investigated. B. longum BAA2573 treatment enhanced M2-macrophage infiltration in intestinal tissues. The levels of cytokine TNF-α and IL-6 in serum were decreased, while IL-10 and TGF-β1 were significantly increased after B. longum BAA2573 pretreatment. RNA-seq identified 202 DEGs between the DSS and B + DSS group, primarily enriched in the activation of the innate immune response and phagocytosis. B. longum BAA2573 may ameliorate immune disorders in colitis mice via regulating the PI3K-AKT and NK-κB signaling pathway. Four genes, Reg3b, Rnf213, Bcl2l15, and Chp2, were significantly associated with the therapeutic effect of B. longum BAA2573. Immune-related signaling were involved in the responses to metabolic disorders. Pretreatment of B. longum BAA2573 demonstrated a promising anti-inflammatory effect in DSS-induced colitis. Supplementation of B. longum BAA2573 during UC development may represent a potential therapeutic approach by effectively maintaining intestinal immune and regulating inflammation-associated cytokines and pathways.